Anticoagulant Use Among Members with Pre-Existing Atrial Fibrillation and Various Pre-Existing Exclusions

Project Title Anticoagulant Use Among Members with Pre-Existing Atrial Fibrillation and Various Pre-Existing Exclusions
Date Posted
Wednesday, May 25, 2016
Project ID
MSY5_MPR05
Status
Complete
Deliverables
Description

Modular program-based one-time assessment of the use of two anticoagulants, warfarin and dabigatran, among members with a pre-existing condition of atrial fibrillation and various pre-existing exclusions, including anemia, COPD, diabetes, hypertension, chronic kidney failure, acute kidney failure, peptic ulcer disease, hospitalized AMI, heart failure, peripheral vascular disease, stroke, urinary catheter, hospitalized bleeding, NSAID use, PPI use, SSRI antidepressant use, thyroid replacement use, insulin use, metformin use, sulfonylureas use, other diabetes management medication use, ACEI/ARB use, anti-arrhythmic use, IV anticoagulant use, antiplatelet use, beta blocker use, calcium channel blocker use, digoxin use, loop diuretic use, potassium-sparing diuretic use, thiazide diuretic use, amiodarone use, and dronedarone use. The query was run against the Mini-Sentinel Distributed Database (MSDD) for the time period of October 19, 2010 to December 31, 2012.  Modular programs are adaptable standardized programs. Results were generated using Modular Program 3, version 1.0; click here for more information.  Queries were distributed in October 2013. This report includes data from 18 Data Partners.

If you are using a web page screen reader and are unable to access this document, please contact the Mini-Sentinel Operations Center for assistance by clicking on the Submit Comments link above or sending an email requesting assistance to info@mini-sentinel.org.

The information contained on this website is provided as part of FDA's commitment to place knowledge acquired from the Mini-Sentinel pilot in the public domain as soon as possible. Please read the disclaimer.

Medical Product
anticoagulant
dabigatran
warfarin
Population / Cohort
All individuals with atrial fibrillation and exclusions
Time Period
October 19, 2010 - December 31, 2012
Assessment Type
Exploratory Analyses
Study Type
Modular Program
Data Sources
Mini-Sentinel Distributed Database (MSDD)
FDA Center
CDER